scale up of taste masked ibuprofen for trials

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience announces successful scale up of taste masked ibuprofen for clinical trials

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reposition medicines, today announces it has completed successful first stage commercial scale up work for its OXPzero™ taste masked ibuprofen.

Over the last few months the Company has been working with a contract manufacturing partner to produce the taste masked ibuprofen in a batch that is both scalable and suitable for product registration.

The Company will now progress to undertake a clinical trial with their co-development partner Hermes Pharma to demonstrate the bio-equivalence of their taste masked ibuprofen, results of which are expected in the first quarter of 2013.

Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented:

"This is a significant step forward in the commercialisation of our OXPzero™ technology. We now have a robust scalable production process and can make GMP grade material which is essential for use in human studies.

Having already demonstrated commercial success for our OXPchew™ technology, with sales growing in Brazil through Aché and partners like Bayer signed, this milestone shows we are making excellent progress towards the commercialisation of our OXPzero™ taste masking technology.

The global ibuprofen market alone is worth $2.7bn and dominated by tablet formulations due to the bitterness and burning sensation of pure ibuprofen. OXPzero allows major brands to formulate high dose non tablet products, without any burn. This milestone is another positive step forward in our confidence that OXPzero will become the leading taste masking technology for all nonsteroidal anti-inflammatory drugs."

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

Hybridan LLP (Broker)

Claire Noyce / Deepak Reddy +44 20 7947 4350

ZAI Corporate Finance (Nominated Adviser)

John Depasquale/ John Treacy +44 20 7060 2220

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The Company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.